{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:00:43Z","timestamp":1759564843295},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[1990,1,1]],"date-time":"1990-01-01T00:00:00Z","timestamp":631152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1990]]},"DOI":"10.1007\/bf00685407","type":"journal-article","created":{"date-parts":[[2004,11,28]],"date-time":"2004-11-28T16:59:32Z","timestamp":1101661172000},"page":"S4-S6","source":"Crossref","is-referenced-by-count":13,"title":["A phase II study of ifosfamide in endometrial cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"C.","family":"Barton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. J.","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Blackledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Mould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A.","family":"Meanwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00647440","volume":"18","author":"V Bramwell","year":"1986","unstructured":"Bramwell V, Mouridsen H, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, Oosterom A van (1986) Cyclophosphamide vs ifosfamide: preliminary report of a randomised phase II trial in adult soft tissue sarcoma. Cancer Chemother Pharmacol 18: 13?16","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR2","volume-title":"BMDP statistical software manual","author":"W Dixon","year":"1985","unstructured":"Dixon W, Brown M, Engelman L, Frane J, Hill M, Jennrich R, Toporek J (1985) BMDP statistical software manual, 5th edn. University of California Press, Berkeley","edition":"5th edn."},{"key":"CR3","unstructured":"FIGO (1985) Annual report on the results of treatment in gynecologic cancer. FIGO report Stockholm 19"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0305-7372(83)80027-9","volume":"10","author":"P Hilgard","year":"1983","unstructured":"Hilgard P, Herdrich K, Brade W (1983) Ifosfamide-current aspects and perspectives. Cancer Treat Rev 10: 183?192","journal-title":"Cancer Treat Rev"},{"key":"CR5","first-page":"96","volume":"9","author":"H Hunter","year":"1982","unstructured":"Hunter H, Harrison E (1982) The anticancer spectrum of ifosfamide. Semin Oncol 9: 96?100","journal-title":"Semin Oncol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0277-5379(86)90368-8","volume":"22","author":"C Meanwell","year":"1986","unstructured":"Meanwell C, Blake E, Kelly K, Honigsberger L, Blackledge G (1986) Prediction of ifosfamide\/mesna associated encephalopathy. Eur J Cancer Clin Oncol 22: 815?819","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR7","first-page":"727","volume":"70","author":"C Meanwell","year":"1986","unstructured":"Meanwell C, Mould J, Blackledge G, Lawton F, Stuart N, Kavanagh J, Latief T, Spooner D, Chetiyawardana A (1986) Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep 70: 727?730","journal-title":"Cancer Treat Rep"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"A Miller","year":"1981","unstructured":"Miller A, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207?214","journal-title":"Cancer"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00006250-198602000-00019","volume":"67","author":"M Piver","year":"1986","unstructured":"Piver M, Lele S, Patsner B, Emrich L (1986) Melphalan, 5-fluorouracil and medroxyprogesterone acetate in metastatic endometrial cancer. Obstet Gynecol 67: 261?264","journal-title":"Obstet Gynecol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00685407\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:10:24Z","timestamp":1554459024000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00685407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990]]},"references-count":9,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1990]]}},"alternative-id":["BF00685407"],"URL":"https:\/\/doi.org\/10.1007\/bf00685407","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990]]}}}